June 1, 2026
Why Medical Information Is Critical to Adverse Event Reporting
Discover the vital role of Medical Information in adverse event reporting and how it enhances patient safety and regulatory compliance in the pharmaceutical industry.
Dedicated, sponsor-aligned medical writers embedded within your organization to provide scalable expertise across the development lifecycle.
When development portfolios expand, organizational structures shift, or internal teams reach capacity; medical writing can quickly become a bottleneck to regulatory progress.
ProPharma's FSP Medical Writing model provides dedicated, sponsor-aligned writers who integrate seamlessly into your organization, delivering continuity, scalability, and deep therapeutic expertise without increasing permanent headcount.
FSP models don't just add capacity, they create meaningful "organizational leverage". By shifting the operational management to the FSP partner, organizations significantly reduce administrative burden and unlock strategic capacity. Internal teams are no longer absorbed by managing the day-to-day execution and can instead focus on high-impact priorities such as advancing scientific strategy, shaping regulatory positions, and driving portfolio-level decisions.
Rather than outsourcing individual documents, this model delivers long-term capability: a stable team that operates within your processes, systems, and governance framework.
For project‑based deliverables, explore our Global Medical Writing & Transparency services.
Many sponsors adopt an FSP model during periods of transition, growth, or sustained volume pressure. Common drivers include:
Dedicated FSP writers function as an extension of your internal medical writing organization. We use your SOPs, templates, quality expectations, systems, and governance structure, participating in established communication and review processes. This embedded approach reduces onboarding time, preserves institutional knowledge, and enables consistent output across programs.
FSP Medical Writing teams can support document development across all stages of the drug development lifecycle:
Publishing in peer-reviewed journals is essential for scientific credibility, regulatory engagement, and clinical adoption. FSP teams provide dedicated support across the publication lifecycle: Manuscripts and abstracts
ProPharma supports biotech, pharmaceutical, and medical device/diagnostics organizations navigating diverse regulatory pathways and evidence requirements. Teams are matched to program complexity, therapeutic area, and modality to ensure relevant expertise and regulatory alignment.
This model is particularly effective when organizations require ongoing support across multiple programs, predictable demand over extended timelines, integration with internal teams, or scalability without hiring delays.
Shifting operational responsibilities can help reduce administrative and operational burden, allowing internal teams to reclaim time and focus. The result is a more agile, strategically aligned writing function that supports faster, more confident organizational progress.
Our FSP Medical Writing solutions provide the stability, expertise, and flexibility needed to sustain development momentum, even as priorities evolve. Contact our team to discuss how an embedded medical writing model can support your organization’s goals.
June 1, 2026
Discover the vital role of Medical Information in adverse event reporting and how it enhances patient safety and regulatory compliance in the pharmaceutical industry.
May 25, 2026
Explore how Medical Information contact centers can enhance medical writing by leveraging their expertise and adaptability in response to evolving demands.
May 27, 2026
ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.
January 27, 2026
ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.
January 31, 2025
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 9, 2024
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
May 20, 2026
When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...
May 20, 2026
A critical CMC change during Phase 3 development led to a partial clinical hold, putting timelines, regulatory alignment, and commercial readiness at risk. In this case study, learn how we partnered...
May 15, 2026
Responding to urgent regulatory safety requests requires balancing speed, scientific rigor, and global compliance. When concerns emerged regarding a potential neurotoxicity signal, the client needed...
June 2, 2026
A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...
April 23, 2026
As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...
April 9, 2026
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...
May 20, 2026
When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...
May 20, 2026
A critical CMC change during Phase 3 development led to a partial clinical hold, putting timelines, regulatory alignment, and commercial readiness at risk. In this case study, learn how we partnered...
May 15, 2026
Responding to urgent regulatory safety requests requires balancing speed, scientific rigor, and global compliance. When concerns emerged regarding a potential neurotoxicity signal, the client needed...
April 9, 2026
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...